Annual report confirms 2021 growth for Hypefactors
Copenhagen, April 06, 2022 (GLOBE NEWSWIRE) -- Announcement no.5-2022
The board of directors of the media tech company Hypefactors has approved the revised annual report for 2021. Revenue for the period amounted to DKK 6,787m, compared to DKK 4,234m in 2020, corresponding to an increase of 60%. Earnings before interest, tax, depreciation, and amortization (EBTIDA) amounted to a negative of DKK 2,073m compared to 2020 which showed a negative EBTIDA of DKK 3,858m. An improvement of 46%*. Hypefactors reached an annual recurring revenue (ARR) of DKK 7,751m per December 31, 2021, (2020: 4,910m) which is an increase over the last twelve months of 58%. The full report is attached and can also be found at www.hypefactors.com/investor
*The EBITDA and improvement percentage numbers are corrected from announcement 5 released April 5, 2022, stating a negative EBITDA of 2.848m and an improvement of 26%.
About Hypefactors A/S
Hypefactors is an integrated AI powered Earned Media tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to a number of facts, incl. automated documentation of the monetary value and quality assessment of each third-party media mention. The platform also contains other time-saving tools such as automatically generated media reports and a mobile app giving access to real-time media mentions. The company is listed at Nasdaq Growth Market in Copenhagen, Denmark.
For more information, please contact:
Casper Janns, CEO: Tlf.: +45 20167481, e-mail: email@example.com
Pierre André Montjovet, Chairman of the Board: Tlf: +41 (0)78 922 33 0,
1306 Copenhagen K
1100 København K
Kim Harpøth Jespersen, Partner, M +4552150243, email: firstname.lastname@example.org
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ted Elvhage, Board member in Fingerprint Cards AB (publ), has sold shares due to private financial commitments19.5.2022 14:14:57 CEST | Press release
Ted Elvhage, Board member in Fingerprint Cards AB, has sold 975,000 shares in Fingerprints. “The reason for my sale of shares is private financial commitments. I have an unchanged strong belief in the company's future and plan to invest in Fingerprints again as soon as it is possible for me to do so,” comments Ted Elvhage. Link to PDMR transactions register. For further information, please contact: Investor Relations: +46(0)10-172 00 10, email@example.com Press: +46(0)10-172 00 20, firstname.lastname@example.org About Fingerprints Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and seamless universe, where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications, and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information visit our website, read our blog, and follow us on
GOGL – Q1 2022 Presentation19.5.2022 13:59:16 CEST | Press release
Please find enclosed the presentation of Golden Ocean Group Limited’s first quarter 2022 results for today’s webcast / conference call at 15:00 CET. Attend by Webcast: Use to the follow link prior to the webcast: https://edge.media-server.com/mmc/p/zgb9bp5w Attend by Conference Call: Applicable dial-in telephone numbers are as follows: International Dial-In: +44 (0) 2071 92 8338 United Kingdom Toll Free: 08002796619 Norway Toll Free: 800 56 865 US Toll-Free: +1 877 870 9135 The presentation material which will be used in the teleconference/webcast can be downloaded on www.goldenocean.bm and replay details will also be available at this website. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Golden Ocean Q1 2022 - Presentation
Vow ASA: Minutes of Annual General Meeting19.5.2022 12:40:04 CEST | Press release
The annual general meeting of Vow ASA was held today on 19 May 2022 at the company's premises at Lysaker Torg 12, 1366 Lysaker, Norway. All matters on the agenda were approved, cf. the notice of the Annual General Meeting that was published on 28 April 2022. The complete minutes are attached to this release. For further information, please contact: Erik Magelssen, CFO, Vow ASA Tel: +47 928 88 728 Email: email@example.com About Vow Vow and its subsidiaries Scanship, C.H. Evensen and Etia are passionate about preventing pollution. The company’s world leading solutions convert biomass and waste into valuable resources and generate clean energy for a wide range of industries. Cruise ships on every ocean have Vow technology inside which processes waste and purifies wastewater. Fish farmers are adopting similar solutions, and public utilities and industries use our solutions for sludge processing, waste management and biogas production on land. With advanced technologies and solution
Bavarian Nordic modtager vaccineordre fra europæisk land efter bekræftede tilfælde af abekopper19.5.2022 11:46:42 CEST | pressemeddelelse
KØBENHAVN, Danmark, 19. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt med et unavngivet europæisk land vedrørende levering af koppevaccinen IMVANEX® i forbindelse med nye tilfælde af abekopper, der er identificeret i løbet af maj 2022. Det første europæiske tilfælde blev bekræftet den 7. maj 2022 hos en person, der vendte hjem fra en rejse til Nigeria, hvor abekopper er naturligt forekommende. Efterfølgende er der bekræftet mere end 20 tilfælde i England, Portugal og Spanien, og flere formodede tilfælde er ved at blive undersøgt. De fleste infektioner lader til at være sket lokalt i de tre lande. I USA er der bekræftet et enkelt tilfælde hos en rejsende fra Canada, hvor der endnu ikke foreligger bekræftede tilfælde, men adskillige formodede tilfælde er ved at blive undersøgt. Bavarian Nordics koppevaccine er godkendt i USA under navnet JYNNEOS® og i Canada under navnet IMVAMUNE®. I begge lande er godkendelsen udvidet til at omfatte abek
Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases19.5.2022 11:46:42 CEST | Press release
COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022. The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation. Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe a